The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 31. On the other hand, if they miss, the stock may move lower. Zacks Consensus Estimate Estimate Revisions Trend Earnings Whisper Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. How Have t ...

The company's first marketed drug, Zulresso (brexanolone), was approved by the FDA in 2019 as the first-ever FDA-approved treatment for adults with postpartum depression (PPD). SAGE markets Zurzuvae in partnership with drug giant Biogen (BIIB) . Sage and BIIB are focused on establishing Zurzuvae as a first-line therapy and the standard of care for women with PPD. Image Source: Zacks Investment Research Last month, the company reported that the phase II SURVEYOR study evaluating dalzanemdor as a potential tr ...

Sage Therapeutics (SAGE) announced that the phase II SURVEYOR study evaluating its lead neuropsychiatric candidate, dalzanemdor (SAGE-718), as a potential treatment for patients with cognition dysfunction caused by Huntington's disease (HD), met its primary endpoint. Shares of the company were however down 2.8% on Jun 11 following the announcement of the news. The SURVEYOR study compared dalzanemdor versus placebo in participants with HD for a 28-day treatment period. The three main objectives of the SURVEY ...

NEW YORK, May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Sage and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On April 17, 2024, Sage ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Ashley Kaplowitz - Vice President-Investor Relations & Capital Markets Barry Greene - Chief Executive Officer & Member-Board of Directors Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Anupam Rama - JPMorgan Ritu Baral - TD Cowen Laura Chico - Wedbush Securiti ...

First Quarter 2024 Financial Results April 25, 2024 Safe Harbor Statement • The slides presented todayand the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as "may," "might," "will," "should," "can," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "opportunity","goal", "mission", "potential," "target", or "continue," and other similar expressions. • Forward-looking statements in this presentation inc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36544 Sage Therapeutics, Inc. (Exact name of registrant as specified in its Charter) Delaware 27-4486580 (State or other juri ...

Exhibit 99.1 Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress Achieved $6.2 million in ZURZUVAE™ (zuranolone) collaboration revenue during the first quarter of 2024, representing 50% of the net revenues reported by Biogen Encouraging initial demand for ZURZUVAE; More than 700 prescriptions shipped and delivered in the first quarter of 2024 Payor coverage now in place for a majority of commercially covered lives for ZURZUVAE in the treatment of wo ...

SAGE Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Conference Call February 14, 2024 8:00 AM ET Company Participants Barry Greene - President, CEO & Director Kimi Iguchi - CFO & Treasurer Laura Gault - Chief Medical Officer Chris Benecchi - Chief Business Officer Ashley Kaplowitz - Director, IR Conference Call Participants Matt Leskowitz - Goldman Sachs Anupam Rama - J.P. Morgan Ritu Baral - TD Cowen James Condulis - Stifel Tazeen Ahmad - Bank of America Brian Abraham - RBC Capital Markets Poorna Kannan ...

2 Chris Benecchi Chief Business Officer Laura Gault Chief Medical Officer Sage Therapeutics © 2024 3 ZURZUVAE First and only oral product approved by the FDA specifically for postpartum depression (second approved product) Sage Therapeutics © 2024 The COVID-19 Pandemic had a significant effect on perinatal mental health outcomes13-15 4 Strong financial foundation to help create value for sustained growth Important Safety Information ZURZUVAE may cause serious side effects, including decreased awareness and ...